反流症状严重程度的评估：方法选择及其特点。
Assessment of reflux symptom severity: methodological options and their attributes.
作者信息
Bytzer P
机构信息
Department of Medicine, Division of Gastroenterology, Glostrup University Hospital, DK-2600 Glostrup, Denmark.
出版信息
Gut. 2004 May;53 Suppl 4(Suppl 4):iv28-34. doi: 10.1136/gut.2003.034298.
Abstract
Despite major advances in our understanding of reflux disease, the management of this disorder still presents many challenges. Reduction of heartburn is the most readily apparent objective for the patient with reflux disease. Thus the ability to measure heartburn accurately is of fundamental importance to clinical research in reflux disease. Here, the available data on the assessment of reflux symptoms--predominantly heartburn--in clinical trials of symptomatic reflux disease are examined.
摘要
尽管我们对反流性疾病的认识取得了重大进展，但这种疾病的管理仍然面临许多挑战。减轻烧心症状是反流性疾病患者最明显的目标。因此，准确测量烧心症状的能力对于反流性疾病的临床研究至关重要。在此，我们将审视在有症状反流性疾病的临床试验中，有关反流症状（主要是烧心）评估的现有数据。
相似文献
1
Assessment of reflux symptom severity: methodological options and their attributes.
Gut. 2004 May;53 Suppl 4(Suppl 4):iv28-34. doi: 10.1136/gut.2003.034298.
2
Gastroesophageal reflux disease: gaining control over heartburn.
Postgrad Med. 1997 Feb;101(2):181-2, 185-7. doi: 10.3810/pgm.1997.02.164.
3
Soothing the burn. Management of gastroesophageal reflux disease.
Adv Nurse Pract. 2004 Jan;12(1):47-50.
4
Refractory Heartburn: A Challenging Problem in Clinical Practice.
Dig Dis Sci. 2018 Mar;63(3):577-582. doi: 10.1007/s10620-018-4927-5. Epub 2018 Jan 20.
5
Heartburn: an overview.
Postgrad Med. 2000 May;107(5 Suppl):3-6. doi: 10.3810/pgm.5.1.2000.suppl3.11.
6
Heartburn in patients with gastro-oesophageal reflux disease in Germany and Sweden: a study on patients' burden of disease.
Pharmacoeconomics. 2003;21(15):1091-102. doi: 10.2165/00019053-200321150-00003.
7
Management of Patients With Functional Heartburn.
Gastroenterology. 2018 Jun;154(8):2018-2021.e1. doi: 10.1053/j.gastro.2018.04.030. Epub 2018 May 3.
8
Functional chest pain responds to biofeedback treatment but functional heartburn does not: what is the difference?
Eur J Gastroenterol Hepatol. 2012 Jun;24(6):708-14. doi: 10.1097/MEG.0b013e3283525a0c.
9
Health-related quality of life improves with treatment-related GERD symptom resolution after adjusting for baseline severity.
Health Qual Life Outcomes. 2003 Nov 29;1:73. doi: 10.1186/1477-7525-1-73.
10
Prevalence of symptoms and use of medication for gastroesophageal reflux in an Australian community.
World J Surg. 2009 Jan;33(1):88-94. doi: 10.1007/s00268-008-9780-9.
引用本文的文献
1
Thailand guideline 2020 for medical management of gastroesophageal reflux disease.
J Gastroenterol Hepatol. 2022 Apr;37(4):632-643. doi: 10.1111/jgh.15758. Epub 2022 Jan 25.
2
Antibiotic Treatment Response in Chronic Lyme Disease: Why Do Some Patients Improve While Others Do Not?
Healthcare (Basel). 2020 Oct 3;8(4):383. doi: 10.3390/healthcare8040383.
3
Removing the Mask of Average Treatment Effects in Chronic Lyme Disease Research Using Big Data and Subgroup Analysis.
Healthcare (Basel). 2018 Oct 12;6(4):124. doi: 10.3390/healthcare6040124.
4
Should I continue taking my acid reflux medication? Design of a pilot before/after study evaluating a patient decision aid.
Can Pharm J (Ott). 2016 Nov 30;150(1):19-23. doi: 10.1177/1715163516679425. eCollection 2017 Jan-Feb.
5
Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non-erosive reflux disease - efficacy of Esoxx, a hyaluronic acid-chondroitin sulphate based bioadhesive formulation.
Aliment Pharmacol Ther. 2017 Mar;45(5):631-642. doi: 10.1111/apt.13914. Epub 2017 Jan 24.
6
Laparoscopic fundoplication for gastroesophageal reflux disease.
World J Gastroenterol. 2014 Oct 21;20(39):14272-9. doi: 10.3748/wjg.v20.i39.14272.
7
Management of gastroesophageal reflux disease: a review of medical and surgical management.
Minim Invasive Surg. 2014;2014:654607. doi: 10.1155/2014/654607. Epub 2014 Feb 17.
8
Is the reflux disease questionnaire useful for identifying GERD according to the Montreal definition?
BMC Gastroenterol. 2014 Jan 22;14:17. doi: 10.1186/1471-230X-14-17.
9
Refractory gastroesophageal reflux disease as diagnosed by impedance-pH monitoring can be cured by laparoscopic fundoplication.
Surg Endosc. 2013 Aug;27(8):2940-6. doi: 10.1007/s00464-013-2861-3. Epub 2013 Feb 23.
10
Age and body mass index: significant predictive factors for successful laparoscopic antireflux surgery.
Surg Today. 2010 Dec;40(12):1137-43. doi: 10.1007/s00595-009-4200-9. Epub 2010 Nov 26.
本文引用的文献
1
Sufficient control of heartburn in endoscopy-negative gastro-oesophageal reflux disease trials.
Scand J Gastroenterol. 2003 Dec;38(12):1197-9. doi: 10.1080/00365520310004920.
2
On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole.
Scand J Gastroenterol. 2002 Jun;37(6):642-7. doi: 10.1080/00365520212499.
3
Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial.
Am J Gastroenterol. 2002 Jun;97(6):1332-9. doi: 10.1111/j.1572-0241.2002.05769.x.
4
Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis.
Am J Gastroenterol. 2002 Mar;97(3):575-83. doi: 10.1111/j.1572-0241.2002.05532.x.
5
A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease.
Aliment Pharmacol Ther. 2002 Mar;16(3):479-85. doi: 10.1046/j.1365-2036.2002.01207.x.
6
Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
Aliment Pharmacol Ther. 2002 Mar;16(3):445-54. doi: 10.1046/j.1365-2036.2002.01181.x.
7
Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial.
Lancet. 2001 Jun 2;357(9270):1738-42. doi: 10.1016/S0140-6736(00)04894-7.
8
Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.
Am J Gastroenterol. 2001 Mar;96(3):656-65. doi: 10.1111/j.1572-0241.2001.3600_b.x.
9
Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months.
Aliment Pharmacol Ther. 2001 Mar;15(3):347-54. doi: 10.1046/j.1365-2036.2001.00943.x.
10
Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
Am J Gastroenterol. 2001 Jan;96(1):27-34. doi: 10.1111/j.1572-0241.2001.03443.x.
Zotero 插件